Corcept Therapeutics Inc
XMUN:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
XMUN:HTD
|
US |
|
K
|
Kinder Morgan Inc
XMUN:2KD
|
US |
|
S
|
Sonic Automotive Inc
F:SA8A
|
US |
|
C
|
Campbell Soup Co
XMUN:CSC
|
US |
|
Caixabank SA
F:48CA
|
ES |
|
C
|
Credit Suisse Group AG
XBER:CSX
|
CH |
|
S
|
Standard Chartered PLC
DUS:STD
|
UK |
|
C
|
CF Industries Holdings Inc
XMUN:C4F
|
US |
|
Fanuc Corp
F:FUCA
|
JP |
|
R
|
RWE AG
PSE:RWE
|
DE |
|
S
|
Shiseido Co Ltd
XMUN:SHD
|
JP |
|
T
|
Tortilla Mexican Grill PLC
F:73D
|
UK |
|
K
|
Kaspi.kz AO
F:KKS
|
KZ |
Wall St Price Targets
HTD Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HTD is 57.87 EUR with a low forecast of 37.41 EUR and a high forecast of 97.23 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HTD's stock price target?
Price Target
57.87
EUR
According to Wall Street analysts, the average 1-year price target for HTD is 57.87 EUR with a low forecast of 37.41 EUR and a high forecast of 97.23 EUR.
What is the Revenue forecast for Corcept Therapeutics Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Corcept Therapeutics Inc?
Projected CAGR
58%
The compound annual growth rate for Operating Income over the next 8 years is 58%.
What is the Net Income forecast for Corcept Therapeutics Inc?
Projected CAGR
36%
The compound annual growth rate for Net Income over the next 8 years is 36%.
